Over 54,000 women are expected to be diagnosed with ovarian cancer in 2002, with prevalence of the disease expected to surpass 100,000 in the seven major pharmaceutical markets. By 2010 the incidence is expected to reach 57,924. Although this figure is lower than that observed for other cancer types, ovarian cancer is still an important focus for healthcare organizations - largely as a consequence of the poor prognosis associated with the disease.
Source: Datamonitor, "Drugs of Tomorrow: Cancer Overview" (DMHC1785)
